Ruike Biotechnology and Ruiji Biotechnology reached an mRNA vaccine cooperation agreement

Taizhou, China, September 29, 2021/PRNewswire/ - Recently, Jiangsu Ruike Biotechnology Co.

This cooperation is a measure taken by the two parties to implement the earlier agreement on strategic cooperation in the field of mRNA infectious disease vaccines

With the mission and vision of “creating first-class vaccines and protecting human health”, Ruike Biotech takes the vaccine business as the main channel and focuses on major innovative vaccines, which covers cervical cancer, new coronary pneumonia, adult tuberculosis, herpes zoster, hand-foot-mouth disease and influenza The powerful vaccine combination of 11 candidate vaccines with a broad spectrum of diseases has accumulated rich experience in vaccine research and development

Ruike Biotechnology has established three technical platforms for new adjuvants, protein engineering and immune evaluation

Regis Biosciences is a biotechnology company with a full technology platform in the field of mRNA technology.

Regis Biosciences is committed to the development of nucleic acid biomedical products and treatment methods such as mRNA

Dr.

Dr.

About Ruike Bio

Ruike Biotechnology is an innovative vaccine company founded in 2012.

About Regis Bio

Shenzhen Ruiji Biotechnology Co.

Forward-looking statement

The information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management regarding future affairs at the time the statement was made